STOCK TITAN
  1. Home
  2. News
  3. CDNA

Caredx Inc - CDNA STOCK NEWS

Welcome to our dedicated news page for Caredx (Ticker: CDNA), a resource for investors and traders seeking the latest updates and insights on Caredx.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Caredx's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Caredx's position in the market.

News
CareDx Reports Preliminary Revenue Results for Fourth Quarter and Full Year 2023
Rhea-AI Summary
CareDx, Inc. (CDNA) reported preliminary financial results for Q4 and full year 2023, with revenue expected to be in the range of $279-280 million, above guidance for fiscal year 2023. Testing Services patient results grew by 4%, while revenue for Patient and Digital Solutions and Products is expected to increase by 29% and 14% year-over-year, respectively. The company repurchased 2.8 million shares of common stock for $26 million and maintained a strong balance sheet with approximately $235 million in cash and cash equivalents and marketable securities, with no debt. However, revenue for the fourth quarter is expected to decrease by approximately 3% compared to the third quarter, driven by the impact of the Medicare Billing Article on Testing Services revenue.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.49%
Tags
earnings
-
News
CareDx Joins Forces with the National Foundation for Transplants to Improve Post-Transplant Medication Adherence
Rhea-AI Summary
CareDx, Inc. (Nasdaq: CDNA) is expanding its reach by offering its Transplant Pharmacy services to National Foundation for Transplants (NFT) patient members to help them manage the complexity of post-transplant medication adherence. The collaboration aims to provide greater support in adhering to complex medication schedules for transplant patients, reducing out-of-pocket costs, and ensuring personalized care with regular touch points.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
13.81%
Tags
none
-
News
CareDx Reports Third Quarter 2023 Results
Rhea-AI Summary
CareDx, Inc. (Nasdaq: CDNA) reported Q3 2023 financial results, including a 7% revenue increase to $67.2 million, raised revenue guidance to $274-278 million for 2023, and maintained a strong balance sheet with $268.2 million in cash and cash equivalents, and marketable securities, with no debt. The company also received Medicare coverage for HeartCare™ and AlloSure® Lung.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
13.9%
Tags
earnings
News
CareDx to Report Third Quarter 2023 Financial Results
Rhea-AI Summary
CareDx, Inc. (Nasdaq: CDNA) will report financial results for the third quarter 2023 on November 8th, 2023. A conference call will be held at 1:30 p.m. PT / 4:30 p.m. ET. Interested individuals can dial 1-800-267-6316 (domestic) or 1-203-518-9783 (international) with Conference ID: CareDx. A live webcast will be available on CareDx's investor relations website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.05%
Tags
conferences earnings
-
News
CareDx Announces CEO Transition
Rhea-AI Summary
CareDx, Inc. announces that Dr. Reginald Seeto will step down as CEO and President and transition to the role of Senior Advisor to the Chairperson. The company will establish an Office of the CEO consisting of Board Chairperson Michael Goldberg, CFO Abhishek Jain, and President of Patient and Testing Services Alexander Johnson. The Board has initiated a search for a permanent CEO. CareDx raises its 2023 revenue guidance to $274-278 million.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.98%
Tags
none
-
News
CareDx Presents New Data at the American Society for Histocompatibility and Immunogenetics Annual Meeting
Rhea-AI Summary
CareDx, Inc. announces a leading presence at the 49th annual meeting of the American Society for Histocompatibility and Immunogenetics (ASHI) to showcase its portfolio of HLA typing solutions and AlloSeq HCT for hematopoietic stem cell monitoring.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.17%
Tags
none
News
CareDx Issues Statement on Supreme Court Decision Regarding Stanford-Licensed Patents
Rhea-AI Summary
The Supreme Court's decision on patent eligibility does not impact CareDx's ability to provide AlloSure®. CareDx disagrees with the decision but believes it applies equally to other transplant diagnostics patents, including Natera's. CareDx has filed a motion to invalidate Natera's patents. CareDx remains committed to improving transplant patient outcomes.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.45%
Tags
none
-
News
Supreme Court Denies CareDx Request for Appeal in Patent Case with Natera
Rhea-AI Summary
The United States Supreme Court has denied CareDx's petition for certiorari in a patent infringement lawsuit against Natera, confirming the invalidity of the asserted patents. This decision upholds previous rulings by the District Court and the Court of Appeals. It effectively terminates any existing claims brought by CareDx against Natera regarding these patents.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.45%
Tags
none
-
News
CareDx To Present at the 2023 Cantor Global Healthcare Conference
Rhea-AI Summary
CareDx, Inc. to present at 2023 Cantor Global Healthcare Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.39%
Tags
conferences
News
CareDx Advances Global Transplant Patient Care at ESOT Congress 2023
Rhea-AI Summary
CareDx presents new clinical data for AlloSeq cfDNA testing solution at ESOT Congress 2023
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.38%
Tags
none
Stock CDNA logo
Caredx Inc

Nasdaq:CDNA

CDNA Rankings

#3073 Ranked by Market Cap
#5231 Ranked by Stock Gains
N/A Ranked by Dividends

CDNA Stock Data

441.67M
50.37M
3.75%
100.35%
10%
Medical Laboratories
Health Care and Social Assistance
Link
US
South San Francisco

About CDNA

caredx: transforming transplant patient care through novel surveillance management solutions caredx, inc. is dedicated to improving the lives of organ transplant patients through non-invasive diagnostics. by combining the latest advances in genomics and bioinformatics technology, with a commitment to generating high quality clinical evidence through trials and registries, caredx is at the forefront of organ transplant surveillance and pre-transplant hla typing solutions. nasdaq:cdna about allosure® allosure is the first and only non-invasive blood test that directly measures allograft injury and identifies the probability of active rejection to better manage kidney transplant patients. allosure is a clinical-grade, proprietary next-generation sequencing (ngs) based test to detect donor-derived cell-free dna (dd-cfdna) in order to identify organ injury in kidney transplant recipients. allosure is analytically validated as a sensitive, specific, and precise measurement of dd-cfdna. allos